CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Charles River Laboratories

Luis Berrade, Sr. Director, Global Biologics Testing Sales, & Ian Wyllie, Director, RightSource Solutions

Rightsource Revolutionizes Biopharma Outsourcing

Luis Berrade

Luis Berrade

Through this article, Luis Berrade and Ian Wyllie from Charles River Laboratories discuss the evolution of biopharmaceutical outsourcing and the limitations of traditional models. They introduce RightSource, a comprehensive lab solution brought directly to client sites, offering faster, more cost-effective, and scalable quality control operations through a servicebased model. This innovative approach addresses the critical needs of biopharmaceutical companies in today’s dynamic landscape.


Over the past few years we have seen some significant changes in the Biopharmaceutical industry. There have been major breakthroughs in new modalities that are changing the lives of patients. Companies are also getting creative in the operating models that they are utilizing to bring drugs to the market. Increasingly companies are trying to focus more on their core competencies while partnering with vendors that complement them well.


We control cost by providing a scalable and high-value service


For many years we saw a push towards insourcing models where a staffing agency would manage some of the staff and areas of operations in a Biopharmaceutical company. This helped companies with some of their cost structure and focus but true partnership was difficult from competing incentives between the two organizations. Many of these contracts were not strategic and came down to how well an organization could recruit and keep talent, while simultaneously keeping the cost of talent down—beyond that there wasn’t much to compete or innovate on.


Unfortunately, this is a result of the structure of these contracts, the vendors would provide basic training and staff but the biopharmaceutical company would have all of their own processes that needed to be followed. This made it very difficult to provide any innovation or build a scalable model.


As a result of this problem, we created a program at Charles River to align incentives and encourage innovation with and for our clients. Our RightSource Platform was made to bring the whole lab to a client site as opposed to just the people—who are still very important. This allowed us to bring in everything from the overarching quality and digital system to individual standard operating procedures (SOP) and test methods.


By bringing in the whole Charles River System we are able to invest heavily in a scalable and highly digitalized program that provides quality control (QC) services to the client. The better we get at this program the more value we can provide to the client and the next client we bring on since it is a scalable model. To align the incentives, we do not charge for the people but rather the services provided as well as penalties on ourselves for the agreed upon metrics. This allows us to hire top talent into our org where they are not the cost we are trying to control. We control cost by providing a scalable and high-value service.


This model has become especially important in recent years where capital is constrained and speed is so critical. Since much of this model is ‘pre-baked’ if a client is building out a new facility, we can setup the QC function in less than half the time and cost since so much of what needs to be established lives in our global system and we are just extending it. There are validation packages that we can just re-execute, SOPs that we can extend and were designed to be extended, etc. As we continue to invest in the model, the benefits will continue to stack on each other.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://biomanufacturing-apac.lifesciencesreview.com/leadership-perspective/rightsource-revolutionizes-biopharma-outsourcing-nwid-2264.html